var data={"title":"Cefepime: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefepime: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5838?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefepime-drug-information\" class=\"drug drug_general\">see &quot;Cefepime: Drug information&quot;</a> and <a href=\"topic.htm?path=cefepime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefepime: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452476\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Maxipime</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147316\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Maxipime</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045931\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cephalosporin (Fourth Generation)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442203\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate infection (Bradley 2016; <i>Red Book</i> [AAP 2015]): IM, IV: 30 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe infection (eg, meningitis, <i>Pseudomonas</i>) (Bradley 2016): <b>Note: </b>Pharmacokinetic studies suggest that every 12-hour dosing provides adequate concentrations for severe infections (including meningitis and pseudomonal infections) during the neonatal period (Lima-Rogel 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body weight &lt;1 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 0 to 14 days: IM, IV: 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &ge;15 days: IM, IV: 50 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body weight 1 to 2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 0 to 7 days: IM, IV: 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &ge;8 days: IM, IV: 50 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body weight &gt;2 kg: IM, IV: 50 mg/kg/dose every 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045922\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cefepime-drug-information\" class=\"drug drug_general\">see &quot;Cefepime: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection: 50 mg/kg/dose every 12 hours; maximum dose: 2,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infection: 50 mg/kg/dose every 8 to 12 hours; maximum dose: 2,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, acute pulmonary exacerbation:</b> Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours; maximum dose: 2,000 mg/dose; patients with more resistant pseudomonal isolates (MIC &ge;16 mg/L) may require 50 mg/kg/dose every 6 hours (Zobell 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, prosthetic valve, treatment within 1 year of replacement:</b> Children and Adolescents: IV: 50 mg/kg/dose every 8 to 12 hours in combination with vancomycin and rifampin for 6 weeks plus gentamicin for the first 2 weeks; maximum dose: 2,000 mg/dose (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Febrile neutropenia, empiric therapy:</b> Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours; maximum dose: 2,000 mg/dose (<i>Red Book</i> [AAP 2015]); duration of therapy dependent upon febrile neutropenia risk-status; in high-risk patients, may discontinue empiric antibiotics if all of the following criteria met: Negative blood cultures at 48 hours; afebrile for at least 24 hours, and evidence of marrow recovery. In low-risk patients, may discontinue empiric antibiotics after 72 hours duration in patients with a negative blood culture and who have been afebrile for 24 hours regardless of marrow recovery status; follow-up closely (Lehrnbecher 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 12 hours in combination with metronidazole; maximum dose: 2,000 mg/dose. <b>Note:</b> IDSA guidelines recommend duration of 4 to 7 days (provided source controlled) (IDSA [Solomkin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis:</b> Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours; maximum dose: 2,000 mg/dose (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis)</b> (ISPD [Warady 2012]): Infants, Children, and Adolescents: Intraperitoneal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent: 15 mg/kg/dose every 24 hours into the long dwell</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous: Loading dose: 500 mg per liter of dialysate; maintenance dose: 125 mg per liter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, moderate to severe:</b> Infants &ge;2 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Due to <i>P. aeruginosa:</i> IV: 50 mg/kg/dose every 8 hours for 10 days; maximum dose: 2,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Not due to P. <i>aeruginosa: </i>IV: 50 mg/kg/dose every 12 hours for 10 days; maximum dose: 2,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections, uncomplicated:</b> Infants &ge;2 months, Children, and Adolescents: IV: 50 mg/kg/dose every 12 hours for 10 days; maximum dose: 2,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection, complicated and uncomplicated:</b> Infants &ge;2 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection: IM, IV: 50 mg/kg/dose every 12 hours for 7 to 10 days; maximum dose: 1,000 mg/dose. <b>Note:</b> IM may only be considered for mild to moderate infections due to <i>E. coli</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infection: IV: 50 mg/kg/dose every 12 hours for 10 days; maximum dose: 2,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Febrile neutropenia, monotherapy:</b> IV: 2,000 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infections, complicated, severe (in combination with metronidazole)</b>: <b>Note:</b> 2010 IDSA guidelines recommend 2,000 mg every 8 to 12 hours for 4 to 7 days (provided source controlled). Not recommended for hospital-acquired intra-abdominal infections (IAI) associated with multidrug-resistant gram-negative organisms or in mild to moderate community-acquired IAIs due to risk of toxicity and the development of resistant organisms (IDSA [Solomkin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Due to <i>P. aeruginosa</i>: IV: 2,000 mg every 8 hours for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Not due to <i>P. aeruginosa</i>: IV: 2,000 mg every 8 to 12 hours for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Due to <i>P. aeruginosa</i>: 2,000 mg every 8 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Not due to <i>P. aeruginosa</i>: 1,000 to 2,000 mg every 8 to 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections, uncomplicated (moderate to severe):</b> IV: 2,000 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infections, complicated and uncomplicated:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate: IM, IV: 500 to 1,000 mg every 12 hours for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe: IV: 2,000 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Infants &ge;2 months, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, similar dosage adjustments to adults would be anticipated based on comparable pharmacokinetics between children and adults.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternative dosing recommendations (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 50 mg/kg/dose every 8 to 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: 50 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 50 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis: 50 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): 50 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Recommended maintenance schedule based on creatinine clearance (may be estimated using the Cockcroft-Gault formula), compared to normal dosing schedule: See table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Cefepime Hydrochloride</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Creatinine Clearance</p>\n            <p style=\"text-indent:0em;\">(mL/minute)</p></th>\n          <th colspan=\"4\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Recommended Maintenance Schedule</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;60</p>\n            <p style=\"text-indent:0em;\">(normal recommended dosing schedule)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 mg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,000 mg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2,000 mg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2,000 mg every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30-60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,000 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2,000 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2,000 mg every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11-29</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,000 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2,000 mg every 24 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;11</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,000 mg every 24 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): 68% removed by hemodialysis: IV: Initial: 1,000 mg (single dose) on day 1. Maintenance: 500 to 1,000 mg every 24 hours <b>or</b> 1,000 to 2,000 mg every 48 to 72 hours (Heintz 2009) <b>or</b> 2,000 mg 3 times weekly after dialysis (Perez 2012). <b>Note:</b> Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis (PD): Removed to a lesser extent than hemodialysis; administer normal recommended dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVH: Loading dose of 2,000 mg followed by 1,000 to 2,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVHD/CVVHDF: Loading dose of 2,000 mg followed by either 1,000 mg every 8 hours <b>or</b> 2,000 mg every 12 hours. <b>Note:</b> Dosage of 1,000 mg every 8 hours results in similar steady-state concentrations as 2,000 mg every 12 hours and is more cost-effective (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Consider higher dosage of 4,000 mg/day if treating <i>Pseudomonas</i> or life-threatening infections in order to maximize time above MIC (Trotman 2005). Dosage of 2,000 mg every 8 hours may be needed for gram-negative rods with MIC &ge;4 mg/L (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No dosage adjustments necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147294\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/50 mL (50 mL); 2 g/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maxipime: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maxipime: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/50 mL (1 ea); 2 g/50 mL (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147278\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045934\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Administer as an intermittent IV infusion over 30 minutes; in adult clinical trials, cefepime has been administered by direct IV injection over 3 to 5 minutes at final concentrations of 40 mg/mL (Garrelts 1999) and 100 mg/mL (Jaruratanasirikul 2002; Lipman 1999) for severe infections </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Administer by deep IM injection into large muscle mass </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2533513\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vials: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. After reconstitution, stable in NS and D<sub>5</sub>W for 24 hours at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) and 7 days at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Refer to the manufacturer's product labeling for other acceptable reconstitution solutions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dual chamber containers: Store unactivated containers at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 85&deg;F). Do not freeze. Following reconstitution, use within 12 hours if stored at room temperature or within 5 days if stored under refrigeration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Premixed solution: Store frozen at -20&deg;C (-4&deg;F). Thawed solution is stable for 24 hours at room temperature or 7 days under refrigeration; do not refreeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045933\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of pneumonia, uncomplicated skin and soft tissue infections, and complicated and uncomplicated urinary tract infections (including pyelonephritis) caused by susceptible organisms, and as empiric therapy for febrile neutropenic patients (FDA approved in ages &ge;2 months and adults); used in combination with metronidazole for complicated intra-abdominal infections (FDA approved in adults); has also been used for the treatment of peritonitis in patients with peritoneal catheters and endocarditis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9645319\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cefepime may be confused with cefixime, cefTAZidime</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147358\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Localized phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hypophosphatemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Eosinophilia, positive direct Coombs test (without hemolysis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Abnormal partial thromboplastin time, abnormal prothrombin time, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity (in patients with a history of penicillin allergy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Agranulocytosis, anaphylactic shock, anaphylaxis, anemia, aphasia, brain disease, <i>Clostridium difficile</i> associated diarrhea, colitis, coma, confusion, decreased hematocrit, erythema, hallucination, hypercalcemia, hyperkalemia, hyperphosphatemia, hypocalcemia, increased blood urea nitrogen, increased serum alkaline phosphatase, increased serum bilirubin, increased serum creatinine, leukopenia, local inflammation, local pain, neurotoxicity, neutropenia, oral candidiasis, pseudomembranous colitis, seizure, status epilepticus (nonconvulsive), stupor, thrombocytopenia, vaginitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147301\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefepime, other cephalosporins, penicillins, other beta-lactam antibiotics, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147282\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: May occur; use caution in patients with a history of penicillin sensitivity; cross-hypersensitivity may occur. If a hypersensitivity reaction occurs, discontinue therapy and institute supportive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Severe neurological reactions (some fatal) have been reported, including encephalopathy, aphasia, myoclonus, seizures, and nonconvulsive status epilepticus. Risk may be increased in the presence of renal impairment; ensure dose adjusted for renal function and discontinue therapy if patient develops neurotoxicity; effects are often reversible upon discontinuation of cefepime.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (CrCl &le;60 mL/minute); dosage adjustments recommended. May increase risk of encephalopathy, myoclonus, and seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Serious adverse reactions have occurred in elderly patients with renal insufficiency given unadjusted doses of cefepime, including life-threatening or fatal occurrences of encephalopathy, myoclonus, and seizures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855565\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The manufacturer does not recommend the use of cefepime in pediatric patients for the treatment of serious infections due to <i>Haemophilus influenzae</i> type b, for suspected meningitis, or for meningeal seeding from a distant infection site. However, limited data suggest that cefepime may be a valuable alternative for treating bacterial meningitis in children in conjunction with other agents like vancomycin in areas with a high incidence of cephalosporin nonsusceptible pneumococci (Haase 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298988\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147287\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13126&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (4th Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147290\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5947925\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Cefepime crosses the placenta.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045930\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged therapy, monitor renal and hepatic function periodically; number and type of stools/day for diarrhea; CBC with differential. Observe  for signs and symptoms of anaphylaxis during first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147281\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysis and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147300\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: IM: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates (Capparelli, 2005):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PMA &lt;30 weeks: 0.51 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PMA &gt;30 weeks: 0.39 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 2 months to 11 years: 0.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 18 L, 0.26 L/kg; penetrates into inflammatory fluid at concentrations ~80% of serum concentrations and into bronchial mucosa at concentrations ~60% of plasma concentrations; crosses the blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding, plasma: ~20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minimally hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 4 to 5 hours (Lima-Rogel 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 months to 6 years: 1.77 to 1.96 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: 13.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous peritoneal dialysis: 19 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: IM: 1 to 2 hours; IV: 0.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (85% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323046\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cefepime HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (50 mL): $31.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/100 mL (100 mL): $51.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cefepime HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $6.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $11.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cefepime-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (1): $13.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 gm/50 mL (1): $20.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Maxipime Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $6.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $10.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Maxipime Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $6.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $11.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147304\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abypym (UA);</li>\n      <li>Acedrin (PY);</li>\n      <li>Alcemax (PH);</li>\n      <li>Amfapime (VN);</li>\n      <li>Axepim (FR);</li>\n      <li>Axera (PH);</li>\n      <li>Biocepime (ID);</li>\n      <li>Caprifim (ID);</li>\n      <li>Cefamax (TH);</li>\n      <li>Cefemax (TW);</li>\n      <li>Cefemet (ID);</li>\n      <li>Cefepima (CO);</li>\n      <li>Ceficad (IN);</li>\n      <li>Cefinov (ID);</li>\n      <li>Cefipex (LB);</li>\n      <li>Cefpas (LK);</li>\n      <li>Cepiram (PH);</li>\n      <li>Deltacef (TR);</li>\n      <li>Dimipra (PH);</li>\n      <li>Epime (LK);</li>\n      <li>Exepime (ID);</li>\n      <li>Falocef (ID);</li>\n      <li>Forgen (BD);</li>\n      <li>Forzyn Beta (PY);</li>\n      <li>Funjapin (TW);</li>\n      <li>Imation (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Interprim (ID);</li>\n      <li>Kuadrotsef (UA);</li>\n      <li>Macef (ID);</li>\n      <li>Macepim (TW);</li>\n      <li>Maxcef (AR, BR, CR, DO, GT, HN, LK, NI, PA, SV, UY);</li>\n      <li>Maxef (MX);</li>\n      <li>Maxfrom (AR);</li>\n      <li>Maxicef (ID, LK);</li>\n      <li>Maxilan (ID);</li>\n      <li>Maxipime (AE, AT, BB, BE, BG, BH, CH, CL, CN, CZ, DE, DK, EC, EE, EG, ES, FI, GR, HK, HR, HU, IT, JO, JP, KR, KW, LB, LT, LU, MX, MY, NL, PE, PK, PL, PT, QA, RU, SA, SE, SG, SI, SK, TR, TW, VE, VN, ZA);</li>\n      <li>Megapime (MY, TH);</li>\n      <li>Pimcef (PE);</li>\n      <li>Pime (TH);</li>\n      <li>Pozineg (ET, QA);</li>\n      <li>Procepim (ID);</li>\n      <li>Protec (AE, KW, QA, SA);</li>\n      <li>Qpime (AE);</li>\n      <li>Rapime (ID);</li>\n      <li>Rovatim (PH);</li>\n      <li>Sanpime (PH);</li>\n      <li>Sefepim (MY);</li>\n      <li>Sefpime (PH, TH);</li>\n      <li>Sepime (PH);</li>\n      <li>Silex (PH);</li>\n      <li>Supecef (TW);</li>\n      <li>Superpime (BD);</li>\n      <li>Tetracef (BD);</li>\n      <li>Tsebopim (UA);</li>\n      <li>Tsepim (UA);</li>\n      <li>Uniceme (VN);</li>\n      <li>Unipim (BD);</li>\n      <li>Vidapime (PH);</li>\n      <li>Vifepime (VN);</li>\n      <li>Zepim (PH);</li>\n      <li>Zepime (PH);</li>\n      <li>Zepym (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arguedas AG, Stutman HR, Zaleska M, et al, &ldquo;Cefepime. Pharmacokinetics and Clinical Response in Patients With Cystic Fibrosis,&rdquo; <i>Am J Dis Child</i>, 1992, 146(7):797-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/1496945/pubmed\" target=\"_blank\" id=\"1496945\">1496945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capparelli E, Hochwald C, Rasmussen M, et al, &quot;Population Pharmacokinetics of Cefepime in the Neonate,&quot; <i>Antimicrob Agents Chemother</i>, 2005, 49(7):2760-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/15980347/pubmed\" target=\"_blank\" id=\"15980347\">15980347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garrelts JC and Wagner DJ, &quot;The Pharmacokinetics, Safety, and Tolerance of Cefepime Administered as an Intravenous Bolus or as a Rapid Infusion,&quot; <i>Ann Pharmacother</i>, 1999, 33(12):1258-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/10630824/pubmed\" target=\"_blank\" id=\"10630824\">10630824</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haase MR, &quot;Acute Bacterial Meningitis in Children,&quot; <i>J Pharm Pract</i>, 2004, 17:392.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, and Dager WE, &quot;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&quot; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaruratanasirikul S, Sriwiriyajan S, and Ingviya N, &quot;Continuous Infusion Versus Intermittent Administration of Cefepime in Patients With Gram-Negative Bacilli Bacteraemia,&quot; <i>J Pharm Pharmacol</i>, 2002, 54(12):1693-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/12542901/pubmed\" target=\"_blank\" id=\"12542901\">12542901</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. <i>J Clin Oncol</i>. 2017;35(18):2082-2094.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28459614/pubmed\" target=\"_blank\" id=\"28459614\">28459614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lima-Rogel V, Medina-Rojas EL, Del Carmen Mil&aacute;n-Segovia R, et al, &quot;Population Pharmacokinetics of Cefepime in Neonates With Severe Nosocomial Infections,&quot; <i>J Clin Pharm Ther</i>, 2008, 33(3):295-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/18452417/pubmed\" target=\"_blank\" id=\"18452417\">18452417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipman J, Wallis SC, and Rickard C, &quot;Low Plasma Cefepime Levels in Critically Ill Septic Patients: Pharmacokinetic Modeling Indicates Improved Troughs With Revised Dosing,&quot; <i>Antimicrob Agents Chemother</i>, 1999, 43(10):2559-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/10508045/pubmed\" target=\"_blank\" id=\"10508045\">10508045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maxipime (cefepime) [prescribing information]. Lake Forest, IL: Hospira; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perez KK, Hughes DW, Maxwell PR, Green K, Lewis JS 2nd. Cefepime for gram-negative bacteremia in long-term hemodialysis: a single-center experience. <i>Am J Kidney Dis</i>. 2012;59(5):740-742.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/22440135/pubmed\" target=\"_blank\" id=\"22440135\">22440135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &quot;Practice Guidelines for the Management of Bacterial Meningitis,&quot; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;(32 Suppl 2):S32-S86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynd MA and Paladino JA, &ldquo;Cefepime: A Fourth-Generation Parenteral Cephalosporin,&rdquo; <i>Ann Pharmacother</i>, 1996, 30(12):1414-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/8968455/pubmed\" target=\"_blank\" id=\"8968455\">8968455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zobell JT, Waters CD, Young DC, et al, &quot;Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: II. Cephalosporins and Penicillins,&quot; <i>Pediatr Pulmonol</i>, 2013, 48(2):107-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/22949297/pubmed\" target=\"_blank\" id=\"22949297\">22949297</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13126 Version 134.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20452476\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F147316\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045931\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442203\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045922\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147294\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F147278\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045934\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2533513\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045933\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9645319\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147358\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147301\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147282\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855565\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298988\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147287\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147290\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5947925\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045930\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147281\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F147300\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323046\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F147304\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13126|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefepime-drug-information\" class=\"drug drug_general\">Cefepime: Drug information</a></li><li><a href=\"topic.htm?path=cefepime-patient-drug-information\" class=\"drug drug_patient\">Cefepime: Patient drug information</a></li></ul></div></div>","javascript":null}